Table 2.
Proportion of patients with response in overall population and various ‘responder’ populations
| Response in | Total population (n = 531) | SBP responders (n = 323) | ACR responders (n = 382) | K responders (n = 349) | Hb responders (n = 383) | Cholesterol responders (n = 325) | Uric acid responders (n = 251) |
|---|---|---|---|---|---|---|---|
| SBP | 323 (61) | 323 (100) | 256 (67) | 208 (60) | 237 (61.9) | 202 (62) | 134 (53) |
| ACR | 382 (72) | 256 (79) | 382 (100) | 262 (75) | 280 (73.1) | 241 (74) | 157 (63) |
| K | 349 (66) | 208 (64) | 262 (69) | 349 (100) | 255 (67) | 217 (67) | 159 (63) |
| Hb | 383 (72) | 237 (73) | 280 (73) | 255 (73) | 383 (100) | 259 (80) | 176 (70) |
| Cholesterol | 325 (61) | 202 (63) | 241 (63) | 217 (62) | 259 (68) | 325 (100) | 150 (60) |
| Uric acid | 251 (47) | 134 (42) | 157 (41) | 159 (46) | 176 (46) | 150 (46) | 251 (100) |
Number of patients (%) with a response to each risk marker. Results are displayed for the total population, and for subsets of responders per risk marker. Chi square tests with a post hoc Bonferroni correction revealed no statistically significant differences.